rs149201802
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_005732.4(RAD50):c.1875C>G(p.Tyr625*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000298 in 1,610,562 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_005732.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD50 | ENST00000378823.8 | c.1875C>G | p.Tyr625* | stop_gained | Exon 12 of 25 | 1 | NM_005732.4 | ENSP00000368100.4 | ||
ENSG00000283782 | ENST00000640655.2 | c.1578C>G | p.Tyr526* | stop_gained | Exon 13 of 26 | 5 | ENSP00000491596.2 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152112Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000796 AC: 20AN: 251244Hom.: 0 AF XY: 0.0000516 AC XY: 7AN XY: 135786
GnomAD4 exome AF: 0.0000261 AC: 38AN: 1458450Hom.: 0 Cov.: 30 AF XY: 0.0000248 AC XY: 18AN XY: 725756
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152112Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74280
ClinVar
Submissions by phenotype
Nijmegen breakage syndrome-like disorder Pathogenic:4
- -
- -
- -
- -
Hereditary cancer-predisposing syndrome Pathogenic:3
This sequence change creates a premature translational stop signal (p.Tyr625*) in the RAD50 gene. RNA analysis indicates that this premature translational stop signal induces altered splicing and may result in an absent or altered protein product. This variant is present in population databases (rs149201802, gnomAD 0.06%). This premature translational stop signal has been observed in individual(s) with pancreatic and breast cancer (PMID: 18281469, 25452441). ClinVar contains an entry for this variant (Variation ID: 220719). Studies have shown that this premature translational stop signal results in skipping of exon 12, and produces a non-functional protein and/or introduces a premature termination codon (internal data). For these reasons, this variant has been classified as Pathogenic. -
This variant is a single amino acid change from Tytosine to a premature translational stop signal at codon 625 of the RAD50 protein. This is expected to result in an absent or disrupted protein product. Truncating variants in RAD50 are known to be pathogenic (PMID: 19409520, 16385572).This variant has been described in the international literature in individuals affected with pancreatic and breast cancer (PMID: 18281469, 25452441) and in individuals undergoing panel testing for hereditary syndrome (PMID: 31159747). The mutation database ClinVar contains entries for this variant (Variation ID: 220719). . -
The p.Y625* pathogenic mutation (also known as c.1875C>G), located in coding exon 12 of the RAD50 gene, results from a C to G substitution at nucleotide position 1875. This changes the amino acid from a tyrosine to a stop codon within coding exon 12. This alteration has been detected in 2/1824 patients with triple-negative breast cancer who were unselected for a family history of breast or ovarian cancer (Couch FJ et al. J Clin Oncol, 2015 Feb;33:304-11). This variant was also reported in 2/1313 early-onset breast cancer cases and 0/1123 population controls (Damiola F et al. Breast Cancer Res, 2014 Jun;16:R58). In addition, this alteration was identified in a 77 year old woman with pancreatic ductal adenocarcinoma and non-Hodgkin's lymphoma and in a male diagnosed with pancreatic cancer (Yurgelun MB et al. Genet Med, 2019 01;21:213-223; Wang X et al. Cancer Res., 2008 Feb;68:971-5). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
not provided Pathogenic:2
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Observed in the heterozygous state in individuals with breast, ovarian, pancreatic, and other cancers (PMID: 18281469, 24240112, 25452441, 29961768, 34887416, 36493725, 39194688); This variant is associated with the following publications: (PMID: 25452441, 29961768, 18281469, 26787654, 24240112, 31159747, 31589614, 37694493, 34887416, 36493725, 39194688, 39778127) -
This nonsense variant causes the premature termination of RAD50 protein synthesis. The frequency of this variant in the general population, 0.00056 (20/35426 chromosomes, http://gnomad.broadinstitute.org), is consistent with pathogenicity. In the published literature, the variant has been reported in individuals with breast cancer (PMID: 25452441 (2015)) and pancreatic cancer (PMID: 29961768 (2019)). It has also been reported in an individual with personal and/or family history of breast and/or ovarian cancer (PMID:31159747 (2019)). Based on the available information, this variant is classified as pathogenic. -
Breast and/or ovarian cancer Pathogenic:1
- -
Hepatocellular carcinoma Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at